A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Prurigo nodularis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Tigercat Pharma
  • Most Recent Events

    • 08 Mar 2017 Results were presented at the 2017 Annual Meeting of the American Academy of Dermatology, according to a Menlo Therapeutics media release.
    • 08 Mar 2017 Results published in a Menlo Therapeutics media release.
    • 08 Mar 2017 Primary endpoint (The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of serlopitant 5 mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis) has been met, according to a Menlo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top